HRP20221325T1 - Pripravci i postupci transmukozne apsorpcije - Google Patents
Pripravci i postupci transmukozne apsorpcije Download PDFInfo
- Publication number
- HRP20221325T1 HRP20221325T1 HRP20221325TT HRP20221325T HRP20221325T1 HR P20221325 T1 HRP20221325 T1 HR P20221325T1 HR P20221325T T HRP20221325T T HR P20221325TT HR P20221325 T HRP20221325 T HR P20221325T HR P20221325 T1 HRP20221325 T1 HR P20221325T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation according
- sublingual
- phosphate
- disease
- condition
- Prior art date
Links
- 238000010521 absorption reaction Methods 0.000 title claims 6
- 238000000034 method Methods 0.000 title claims 5
- 239000000203 mixture Substances 0.000 title claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 claims 3
- 229960003572 cyclobenzaprine Drugs 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- UZLGHNUASUZUOR-UHFFFAOYSA-L dipotassium;3-carboxy-3-hydroxypentanedioate Chemical compound [K+].[K+].OC(=O)CC(O)(C([O-])=O)CC([O-])=O UZLGHNUASUZUOR-UHFFFAOYSA-L 0.000 claims 1
- 239000002526 disodium citrate Substances 0.000 claims 1
- 235000019262 disodium citrate Nutrition 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 1
- 235000019799 monosodium phosphate Nutrition 0.000 claims 1
- 235000011056 potassium acetate Nutrition 0.000 claims 1
- 239000011736 potassium bicarbonate Substances 0.000 claims 1
- 235000015497 potassium bicarbonate Nutrition 0.000 claims 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 235000011181 potassium carbonates Nutrition 0.000 claims 1
- 239000001508 potassium citrate Substances 0.000 claims 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000006190 sub-lingual tablet Substances 0.000 claims 1
- 229940098466 sublingual tablet Drugs 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- 235000015870 tripotassium citrate Nutrition 0.000 claims 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 claims 1
- 235000019798 tripotassium phosphate Nutrition 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
- 235000019263 trisodium citrate Nutrition 0.000 claims 1
- 229940038773 trisodium citrate Drugs 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims 1
- 235000019801 trisodium phosphate Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
Claims (9)
1. Pripravak prikladan za oralnu transmukoznu apsorpciju koji sadrži farmaceutski prihvatljivu sol ciklobenzaprina i sredstvo za baziranje.
2. Pripravak prema zahtjevu 1, naznačen time što je oralna transmukozna apsorpcija sublingvalna apsorpcija.
3. Pripravak prema zahtjevu 2, naznačen time što je pripravak u obliku odabranom iz skupine koju čine sublingvalna tableta, sublingvalni film, sublingvalni prašak, i sublingvalna otopina za raspršivanje.
4. Pripravak prema bilo kojem od zahtjeva 1 do 3, naznačen time što je farmaceutski prihvatljiva sol ciklobenzaprina ciklobenzaprin HCl.
5. Pripravak prema bilo kojem od zahtjeva 1 do 4, naznačen time što je sredstvo za baziranje odabrano iz skupine koju čine kalijev dihidrogen fosfat, dikalijev hidrogen fosfat, trikalijev fosfat, natrijev karbonat, natrijev bikarbonat, kalcijev karbonat, kalcijev bikarbonat, TRIS pufer, natrijev dihidrogen fosfat, dinatrijev hidrogen fosfat, trinatrijev fosfat, kalijev karbonat, kalijev bikarbonat, kalijev acetat, natrijev acetat, dikalijev citrat, trikalijev citrat, dinatrijev citrat i trinatrijev citrat.
6. Pripravak prema zahtjevu 5, naznačen time što je sredstvo za baziranje dikalijev hidrogen fosfat.
7. Pripravak prema zahtjevu 5, naznačen time što je sredstvo za baziranje kalijev dihidrogen fosfat.
8. Pripravak prema bilo kojem od zahtjeva 1 do 7 za uporabu u postupku za liječenje bolesti ili stanja kod pojedinca, pri čemu postupak uključuje davanje navedenog pripravka transmukoznom apsorpcijom, pri čemu je bolest ili stanje posttraumatski stresni poremećaj (PTSP).
9. Pripravak prema bilo kojem od zahtjeva 1 do 7 za uporabu u postupku za liječenje bolesti ili stanja kod pojedinca, pri čemu postupak uključuje davanje navedenog pripravka transmukoznom apsorpcijom, pri čemu je bolest ili stanje odabrano iz skupine koju čine fibromijalgija, depresija, traumatska ozljeda mozga, poremećaj spavanja, san koji se ne obnavlja, kronična bol, spazam mišića, i anksiozni poremećaj.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660593P | 2012-06-15 | 2012-06-15 | |
| US201261667774P | 2012-07-03 | 2012-07-03 | |
| US201261725402P | 2012-11-12 | 2012-11-12 | |
| US201361792900P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/046023 WO2013188847A1 (en) | 2012-06-15 | 2013-06-14 | Compositions and methods for transmucosal absorption |
| EP13804115.7A EP2861223B1 (en) | 2012-06-15 | 2013-06-14 | Compositions and methods for transmucosal absorption |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221325T1 true HRP20221325T1 (hr) | 2022-12-23 |
Family
ID=49758769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221325TT HRP20221325T1 (hr) | 2012-06-15 | 2013-06-14 | Pripravci i postupci transmukozne apsorpcije |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20140171515A1 (hr) |
| EP (1) | EP2861223B1 (hr) |
| JP (5) | JP6259452B2 (hr) |
| CN (2) | CN111388430A (hr) |
| AR (1) | AR092330A1 (hr) |
| AU (2) | AU2013274003B2 (hr) |
| BR (1) | BR112014031394B1 (hr) |
| CA (2) | CA2876902C (hr) |
| DK (1) | DK2861223T3 (hr) |
| ES (1) | ES2929133T3 (hr) |
| HK (1) | HK1209361A1 (hr) |
| HR (1) | HRP20221325T1 (hr) |
| HU (1) | HUE060175T2 (hr) |
| IL (1) | IL236268B (hr) |
| LT (1) | LT2861223T (hr) |
| MX (2) | MX2021005317A (hr) |
| MY (1) | MY194495A (hr) |
| NZ (2) | NZ631144A (hr) |
| PL (1) | PL2861223T3 (hr) |
| PT (1) | PT2861223T (hr) |
| RS (1) | RS63822B1 (hr) |
| SG (2) | SG11201408318RA (hr) |
| SI (1) | SI2861223T1 (hr) |
| TW (3) | TWI683660B (hr) |
| WO (1) | WO2013188847A1 (hr) |
| ZA (1) | ZA201500288B (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2501234T3 (pl) | 2009-11-20 | 2018-01-31 | Tonix Pharma Holdings Ltd | Sposoby i kompozycje stosowane w leczeniu dolegliwości związanych z zespołem stresu pourazowego z użyciem cyklobenzapryny |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| DK2968992T3 (da) | 2013-03-15 | 2020-02-03 | Tonix Pharma Holdings Ltd | Eutetiske formuleringer af cyclobenzaprinhydrochlorid og mannitol |
| SG11201701995PA (en) * | 2014-09-18 | 2017-04-27 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| KR20180035219A (ko) * | 2015-07-15 | 2018-04-05 | 테라네수스 | 뇌의 헤미채널을 차단하기 위한 아미트리프틸린의 용도 및 이의 생체 내 효과 증진 방법 |
| WO2018045367A1 (en) * | 2016-09-02 | 2018-03-08 | Nova Southeastern University | Atropine sulfate rapidly-disintegrating sublingual tablets for treatment of acute organophosphate toxicity |
| CA3069699A1 (en) * | 2017-07-13 | 2019-01-17 | Tonix Pharmaceuticals Holding Corp. | Analogs of cyclobenzaprine and amitryptilene |
| CN107519142B (zh) * | 2017-08-24 | 2021-02-26 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下片及其制备方法 |
| CN107496355B (zh) * | 2017-08-24 | 2021-04-30 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下喷雾剂及其制备方法 |
| ES2930376T3 (es) * | 2017-12-08 | 2022-12-09 | Hoffmann La Roche | Formulación farmacéutica |
| SG11202004799TA (en) | 2017-12-11 | 2020-06-29 | Tonix Pharma Holdings Ltd | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
| CN108721240A (zh) * | 2018-06-08 | 2018-11-02 | 华益药业科技(安徽)有限公司 | 一种25mg阿米替林薄膜包衣片处方和工艺规程 |
| MX2021002012A (es) | 2018-08-20 | 2021-04-28 | Tonix Pharma Holdings Ltd | Metodos de tratamiento del trastorno por estres agudo y trastorno por estres postraumatico. |
| CA3156118A1 (en) * | 2019-09-30 | 2021-04-08 | Cadila Healthcare Limited | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CYCLOBENZAPRINE |
| JP2023521167A (ja) * | 2020-04-08 | 2023-05-23 | トニックス ファーマシューティカルズ ホールディング コーポレーション | 性機能障害のシクロベンザプリン処置 |
| EP4247370A1 (en) * | 2020-11-20 | 2023-09-27 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for alcohol use disorder |
| EP4255407A1 (en) | 2020-12-07 | 2023-10-11 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for fibromyalgia |
| WO2022170107A2 (en) | 2021-02-04 | 2022-08-11 | Tonix Pharmaceuticals Holding Corp. | An improved method of assessing clinical response in the treatment of ptsd symptoms |
| WO2023059728A1 (en) | 2021-10-06 | 2023-04-13 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients |
| WO2023250036A1 (en) | 2022-06-21 | 2023-12-28 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| WO1999018937A1 (en) * | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
| DK1077683T3 (da) * | 1998-05-14 | 2003-03-31 | Alza Corp | Antidepressiv behandling |
| EP1202721A1 (en) | 1999-08-13 | 2002-05-08 | Vela Pharmaceuticals Inc. | Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| PT1202722E (pt) | 1999-08-13 | 2005-11-30 | L & L Technologies Llc | Usos para o tratamento ou prevencao de disturbios do sono usando doses muito baixas de ciclobenzaprina |
| AU2001261744A1 (en) * | 2000-05-19 | 2001-12-03 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| WO2002094229A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of muscle relaxants through an inhalation route |
| WO2004071491A1 (en) * | 2003-02-04 | 2004-08-26 | Chrysalis Technologies Incorporated | Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem |
| US20090117054A1 (en) * | 2005-03-29 | 2009-05-07 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US20090148532A1 (en) * | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
| JP2009079060A (ja) * | 2008-10-15 | 2009-04-16 | Novadel Pharma Inc | 極性または非極性の、バッカルスプレーまたはカプセル |
| US20100266682A1 (en) * | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| US20100247586A1 (en) * | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| PL2501234T3 (pl) * | 2009-11-20 | 2018-01-31 | Tonix Pharma Holdings Ltd | Sposoby i kompozycje stosowane w leczeniu dolegliwości związanych z zespołem stresu pourazowego z użyciem cyklobenzapryny |
| US20110319389A1 (en) * | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| ITMI20110558A1 (it) * | 2011-04-06 | 2012-10-07 | Campiglio Consulting Srl | Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale |
| DK2968992T3 (da) * | 2013-03-15 | 2020-02-03 | Tonix Pharma Holdings Ltd | Eutetiske formuleringer af cyclobenzaprinhydrochlorid og mannitol |
-
2013
- 2013-06-14 CA CA2876902A patent/CA2876902C/en active Active
- 2013-06-14 MX MX2021005317A patent/MX2021005317A/es unknown
- 2013-06-14 TW TW107117266A patent/TWI683660B/zh active
- 2013-06-14 US US13/918,692 patent/US20140171515A1/en active Pending
- 2013-06-14 PL PL13804115.7T patent/PL2861223T3/pl unknown
- 2013-06-14 CN CN202010024102.2A patent/CN111388430A/zh active Pending
- 2013-06-14 CA CA3118913A patent/CA3118913C/en active Active
- 2013-06-14 TW TW102121267A patent/TWI590820B/zh active
- 2013-06-14 WO PCT/US2013/046023 patent/WO2013188847A1/en active Application Filing
- 2013-06-14 MX MX2014015436A patent/MX2014015436A/es unknown
- 2013-06-14 TW TW106117185A patent/TWI642429B/zh active
- 2013-06-14 DK DK13804115.7T patent/DK2861223T3/da active
- 2013-06-14 MY MYPI2014703784A patent/MY194495A/en unknown
- 2013-06-14 RS RS20221005A patent/RS63822B1/sr unknown
- 2013-06-14 AU AU2013274003A patent/AU2013274003B2/en active Active
- 2013-06-14 CN CN201380039522.6A patent/CN104684550A/zh active Pending
- 2013-06-14 JP JP2015517469A patent/JP6259452B2/ja active Active
- 2013-06-14 PT PT138041157T patent/PT2861223T/pt unknown
- 2013-06-14 HR HRP20221325TT patent/HRP20221325T1/hr unknown
- 2013-06-14 SI SI201332010T patent/SI2861223T1/sl unknown
- 2013-06-14 BR BR112014031394-6A patent/BR112014031394B1/pt active IP Right Grant
- 2013-06-14 SG SG11201408318RA patent/SG11201408318RA/en unknown
- 2013-06-14 AR ARP130102101A patent/AR092330A1/es not_active Application Discontinuation
- 2013-06-14 SG SG10201605407TA patent/SG10201605407TA/en unknown
- 2013-06-14 EP EP13804115.7A patent/EP2861223B1/en active Active
- 2013-06-14 NZ NZ631144A patent/NZ631144A/en unknown
- 2013-06-14 ES ES13804115T patent/ES2929133T3/es active Active
- 2013-06-14 HU HUE13804115A patent/HUE060175T2/hu unknown
- 2013-06-14 LT LTEPPCT/US2013/046023T patent/LT2861223T/lt unknown
- 2013-06-14 NZ NZ726488A patent/NZ726488A/en unknown
-
2014
- 2014-12-15 IL IL236268A patent/IL236268B/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00288A patent/ZA201500288B/en unknown
- 2015-10-16 HK HK15110186.6A patent/HK1209361A1/xx unknown
-
2017
- 2017-10-02 JP JP2017192713A patent/JP2017222726A/ja not_active Withdrawn
-
2018
- 2018-10-04 AU AU2018241128A patent/AU2018241128B2/en active Active
-
2019
- 2019-05-14 JP JP2019091262A patent/JP2019123757A/ja not_active Withdrawn
-
2021
- 2021-06-16 JP JP2021100154A patent/JP2021138765A/ja not_active Withdrawn
-
2024
- 2024-02-02 JP JP2024014696A patent/JP2024032964A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221325T1 (hr) | Pripravci i postupci transmukozne apsorpcije | |
| JP2015534562A5 (hr) | ||
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| HRP20240231T1 (hr) | Farmaceutske formulacije inhibitora brutonove tirozin kinaze | |
| JP2013231087A5 (hr) | ||
| HRP20161680T1 (hr) | Farmaceutski pripravak koji sadrži ne-nukleozidni inhibitor reverzne transkriptaze | |
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| JP2015038135A5 (hr) | ||
| HRP20151444T4 (hr) | Sredstva za liječenje i postupci liječenja dlbcl | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| NZ593475A (en) | Calcium salts for reducing exhalation of infectious bioaerosol particles | |
| MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| JP2014218522A5 (hr) | ||
| AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
| HRP20191723T1 (hr) | Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa | |
| EA201590933A1 (ru) | Новые перорально биодоступные соединения, модулирующие контроль дыхания, и способы их использования | |
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| HRP20191710T1 (hr) | Postupci za liječenje poremećaja ciklusa uree | |
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| HRP20171678T1 (hr) | Postupci za smanjenje prejedanja ili kompulzivnog jedenja | |
| JP2011511793A5 (hr) | ||
| BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
| HRP20192227T1 (hr) | Dvojna uporaba oralnog farmaceutskog pripravka tableta sulfatnih soli i metode njihove uporabe | |
| HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru |